Stock Analysis of Adaptive Biotechnologies Corp (ADPT) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ADPT
Close 3.61
Change -0.110 / 2.96 %
Volume 1573.00 K
Vol Change -261157.00 / 14.24 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bullish
Growth Index Very Low Growth Stock
Value Index Very Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of Adaptive Biotechnologies Corp
PE (TTM)

-2.43

Very Poor
Price / Book

1.48

Good
Price / Sales

3.00

Poor
Piotroski F Score

2.0

Poor
Market Cap

531998 K

Enterprise Value

476318 K

ROA (TTM)

-30.25

Very Poor
ROE (TTM)

-60.92

Very Poor
Net Margin (TTM)

-123.24

Very Poor
Revenue

3.03 %

179690 K
Net Profit

2.12 %

-195937.00 K
Debt to Equity

0.0304

Excellent
Altman Z Score

-1.57

Very Poor
Quick Ratio

4.50

Very Good
Cash Ratio

3.94

Very Good


Highs/Lows of Adaptive Biotechnologies Corp
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week3.5 3.14 % 1.54 % 4.23.514-May-2413-May-24
Two Week3.01 19.93 % 3.42 % 4.23.0114-May-2406-May-24
One Month2.44 47.95 % 5.60 % 4.22.2814-May-2419-Apr-24
Three Month3.85 6.23 % 5.95 % 4.3452.2828-Feb-2419-Apr-24
Six Months4.31 16.24 % 17.48 % 5.492.2828-Dec-2319-Apr-24
One year6.25 42.24 % 27.52 % 9.0682.2814-Jun-2319-Apr-24
Two year8.21 56.03 % 29.70 % 10.792.2818-Jan-2319-Apr-24


Technical View of Adaptive Biotechnologies Corp
RSI

60.11

Neutral
MACD

0.237

Bullish
ADX

30.70

Bullish
Super Trend

3.12

Mild Bullish
Williams %R

-35.98

Neutral
CCI

77.36

Strong Bearish


EMA 5

3.69

Strong Bearish
EMA 15

3.40

Bullish
EMA 50

3.25

Strong Bullish
EMA 100

3.59

Strong Bullish
SMA 100

3.60

Strong Bullish
SMA 200

4.40

Mild Bearish
SMA 5 / 20

3.80 / 3.13

Strong Bullish
SMA 15 / 50

3.31 / 3.06

Strong Bullish
SMA 50 / 200

3.06 / 4.40

Strong Bearish




Charts of Adaptive Biotechnologies Corp


Returns of Adaptive Biotechnologies Corp with Peers
Period / StockADPTCMPSIRMDALEC
1 Week3.14%-0.254%-3.58%3.62%
1 Mth47.95%-8.09%3.85%7.30%
3 Mth-6.23%-25.40%-7.59%-14.60%
6mth-16.24%30.45%-0.450%26.22%
1 Year-42.24%-7.76%-8.31%-28.61%
2 Year-56.03%-12.60%28.18%-40.29%
5 Years--86.72%-73.22%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Adaptive Biotechnologies Corp with Peers
Ratio / StockADPTCMPSIRMDALEC
PE-2.43-775.0729.87-947.11
P/B1.48470.497.53668.08
ROA-30.25-51.0821.10-17.81
ROE-60.92-60.7025.21-70.54
Debt To Equity0.03040.1380.00600.063
Revenue179690 K
3.03 % 		0
% 		62973.71 K
18.14 % 		96312.00 K
27.92 %
Net Income-195937.00 K
2.12 % 		-116858.00 K
27.71 % 		16326.71 K
27.28 % 		-141385.00 K
6.06 %


Technicals of Adaptive Biotechnologies Corp with Peers
Technical / StockADPTCMPSIRMDALEC-
ADX30.7016.4520.1913.89
CMF-0.0186-0.282-0.064-0.102
MFI69.9047.7747.2362.98
RSI60.1139.0447.1849.91
MACD Abv SignalTrueTrueFalseTrue
Price Above 50 MATrueFalseFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : Adaptive Biotechnologies Corp

Address : 1165 Eastlake Avenue East, Seattle, WA, United States, 98109
Tel : 206 659 0067
URL : https://www.adaptivebiotech.com
Code : ADPT, ISIN : US00650F1093, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 27_Jun_2019
Employee Count : 709

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.


Note : All Data Generated at the End of Trading Hours (EOD Data)